Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2010-09-01 08:00 |
Transgene obtient un avis scientifique positif de l'Agence Européenne des Médic…
|
French | 27.0 KB | ||
| 2010-07-12 17:45 |
Transgene announces opening of First clinical site for its Phase II trial of TG…
|
English | 25.5 KB | ||
| 2010-07-12 17:45 |
Transgene : ouverture du premier centre clinique pour la phase II de TG4040 con…
|
French | 29.8 KB | ||
| 2010-06-17 17:45 |
TRANSGENE ANNONCE DES MODIFICATIONS AU SEIN DE SON CONSEIL D'ADMINISTRATION
|
French | 27.8 KB | ||
| 2010-06-17 17:45 |
Transgene announces changes to its Board of Directors
|
English | 19.8 KB | ||
| 2010-06-03 17:45 |
Transgene announces successful rights issue
|
English | 53.7 KB | ||
| 2010-06-03 17:45 |
TRANSGENE annonce le succès de son augmentation de capital
|
French | 76.9 KB | ||
| 2010-05-11 14:45 |
TRANSGENE : Rapport financier trimestriel - Période du 1er janvier au 31 mars 2…
|
French | 32.8 KB | ||
| 2010-05-11 14:45 |
TRANSGENE : Rapport financier trimestriel - Période du 1er janvier au 31 mars 2…
|
French | 32.8 KB | ||
| 2010-05-10 08:00 |
Transgene annonce le lancement d'une augmentation de capital avec maintien du …
|
French | 81.7 KB | ||
| 2010-05-10 08:00 |
Transgene announces the launch of a capital increase with preferential subscrip…
|
English | 43.7 KB | ||
| 2010-04-19 17:45 |
TRANSGENE: Cash position of E55.7m as of 31st March 2010
|
English | 21.3 KB | ||
| 2010-04-19 17:45 |
Transgene : trésorerie de 55,7 ME au 31 mars 2010
|
French | 17.9 KB | ||
| 2010-04-15 19:59 |
Transgene : communique de mise à disposition du document de référence 2009
|
French | 12.4 KB | ||
| 2010-03-23 20:10 |
TRANSGENE ANNONCE UN PROJET D'AUGMENTATION DE SES FONDS PROPRES
|
French | 25.8 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
